Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
5 min read
Angiochem Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Angiochem, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Encoded Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Encoded Therapeutics, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Heat Biologics, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Heat Biologics, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Biofrontera AG Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Biofrontera AG, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Active Biotech AB (publ) Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Active Biotech AB (publ), covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Gritstone bio, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Gritstone bio, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
AptaBio Therapeutics Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of AptaBio Therapeutics Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Elasmogen Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Elasmogen, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Burzynski Research Institute, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Burzynski Research Institute, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Alligator Bioscience AB (publ) Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Alligator Bioscience AB (publ), covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
EyeGene Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of EyeGene Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
FibroGen, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of FibroGen, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.